- FDA Approved
- Plaque Psoriasis (moderate to severe, candidates for systemic therapy or Phototherapy)
- Guselkumab (Tremfya)
- Risankizumab (Skyrizi)
- Tildrakizumab (Ilumya)
- Active Psoriatic Arthritis
- Guselkumab (Tremfya)
- Risankizumab (Skyrizi)
-
Crohn's Disease (adults with moderate to severe active disease)
- Risankizumab (Skyrizi)
- Interleukin 23 Inhibitor (IL23 Inhibitor)
- The Cytokines IL-23 and IL-17 are released from activated myeloid Dendritic Cells and Macrophages
- Cytokines (e.g. IL-23) trigger a proinflammatory cascade, activating immune cells (e.g. T cells)
- Angiogenesis
- Keratinocyte proliferation
- Immune cells migrate to within psoriatic lesions
- IL23 Monoclonal antibodies
- Self-injectable agents that target IL23
- Suppress IL23-triggered inflammatory response
- Guselkumab (Tremfya)
- Plaque Psoriasis or Psoriatic Arthritis (Adults): 100 mg SQ at Week 0, Week 4 and then every 8 weeks
- Risankizumab (Skyrizi)
- Plaque Psoriasis or Psoriatic Arthritis (Adults): 150 mg SQ at Week 0, Week 4, then every 12 weeks
- Crohn's Disease (Adults)
- IV Induction Start: 600 mg IV infusion over 1 hour at week 0, week 4 and week 8
- SQ Maintenance (follows IV course): 180 mg or 360 mg SQ at week 12, then every 8 weeks
- Monitor for hepatotoxicity at least during IV induction course at baseline and periodically in first 12 weeks
- Tildrakizumab (Ilumya)
- Plaque Psoriasis (Adults): 100 mg SQ at Week 0 and Week 4, and then every 12 weeks
- Serious
- Hypersensitivity Reaction (including Anaphylaxis)
- Serious Infections
- Tuberculosis activation
- Test for Tuberculosis before initiating agents
- Common
- Infections (URI, UTI, dermatophyte fungal infections, HSV)
- Headache
- Arthralgias
- Gastroenteritis (including Diarrhea)
- Unknown safety in pregnancy
- Unknown safety in Lactation
-
Live Vaccines
- Avoid concurrently with IL-23 inhibitors
- Guselkumab (DailyMed)
- Risankizumab (DailyMed)
- Tildrakizumab (DailyMed)